AMENDMENTS TO THE SPECIFICATION:

Please replace the Title with the following new Title:

--METHODS FOR OBTAINING NUCLEOTIDE SEQUENCES CODING FOR POLYPEPTIDES SPECIFICALLY ACTIVE FOR LARVAE OF *S. littoralis*--

Please add the following new paragraph immediately before the paragraph beginning at page 1, line 1:

--This is a continuation of Application No. 09/583,717, filed May 30, 2000 (allowed), which is a continuation of Application No. 08/461,750, filed June 5, 1995 (now U.S. Patent No. 6,110,734), which is a continuation of Application No. 08/251,652, filed May 31, 1994 (abandoned), which is a continuation of Application No. 08/094,382, filed July 21, 1993 (abandoned), which is a continuation of Application No. 07/458,754, filed December 11, 1989 (abandoned), all of which are incorporated herein by reference for all purposes. Applicants claim benefit of priority to Application No. 87/08090, filed June 10, 1987, in France, Application No. 88 401 121, filed May 6, 1988, in Europe, and International Application No. PCT/FR88/00292, filed June 9, 1988, all of which are incorporated herein by reference for all purposes. This application is also related to Application No. 09/918,485, filed August 1, 2001, which is a divisional of Application No. 09/ 037,621, filed May 10, 1998 (now U.S. Patent No. 6,310,035), which is a divisional of Application No. 08/461,551, filed June 5, 1995 (now U.S. Patent No. 5,792,928).--

Please insert the following centered heading at page 1, between lines 15 and 16:

--BACKGROUND OF THE INVENTION--

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Please insert the following centered heading at page 2, between lines 5 and 6:

--SUMMARY OF THE INVENTION--

Please insert the following centered heading at page 4, before line 1:

--DETAILED DESCRIPTION OF THE INVENTION--

Please replace the paragraph beginning at page 4, line 1 with the following amended paragraph:

--A sequence of nucleotides according to the invention is characterized in that it has the capacity to hybridize with a probe formed from the sequence (I) showing the following chain arrangement (nucleotides 52-990 of SEQ ID NO:1):--

Please replace the paragraph beginning at page 5, line 26, with the following amended paragraph:

--The invention also relates to a sequence of nucleotides coding for the following sequence (II) of amino acids (amino acids 1-250 of SEQ ID NO:2):--

Please replace the paragraph beginning at page 7, line 10, with the following amended paragraph:

--Another sequence of nucleotides of the invention is characterized by its capacity of hybridization with a probe formed from the sequence (III) showing the following chain arrangement (SEQ ID NO: 1):--

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Please replace the paragraph beginning at page 11, line 31, with the following amended paragraph:

--The invention also relates to sequence of nucleotides characterized in that it codes for a polypeptide containing the sequence (IV) of amino acids below (SEQ ID NO:2):--

Please insert the following centered heading at page 21, between lines 9 and 10:

--BRIEF DESCRIPTION OF THE DRAWINGS--

Please replace the paragraph beginning at page 21, line 10 with the following amended paragraph:

--Other characteristics and advantages of the invention will become apparent in the course of the description and in referring to the examples in which:

-figure 1 presents the restriction map of the plasmids pHTA6 and pHTE6,

-figure 2, the restriction map of a gene for a crystal protein of the aizawai 7-29 strain cloned in the plasmid pHTA2 and deining the DNA fragments which are used as probe,

-figure 3 shows the fragment of 6.6 kb cloned in pHTA2 and the result of a hybridization carried out between this fragment and the probes described in figure 2,

-figure 4, the restriction map of the plasmid pHT671, and

-figure 5, the photographs of the immunodiffusion tests. In figure 5A an antiserum against all of the δ-endotoxins of aizawai 7-29, containing rabbit antibodies

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

directed against the solubilized crystal protein, was used in the central well. In figure 5B, an antiserum containing rabbit polyclonal antibodies against the crystal proteins of Berliner 1715 was used. In figures 5A and 5B, solubilized, purified crystal of aizawai 7-29 was placed in well No. 1 to serve as a positive control; and wells No. 2, 3, 4, 5, and 6 contained E. coli clones containing the plasmids pHT671, pHTA4, pHTA2, pHT71 and pUC18, respectively.--

Please insert the attached Sequence Listing into the application before the claims, and renumber the pages of the specification accordingly.

Please insert, after the last page of the claims, the Abstract which is provided on a separate sheet.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com